SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: Biomaven who wrote (1348)7/25/2000 2:43:01 PM
From: rkrw  Respond to of 52153
 
I find CBST and daptomycin to be a mystery as well.
As far as LLY, if it is a future $1B drug, they screwed up, but that said, as I understand it, LLY is to receive a sizable royalty rate, well into the double digits.

Ironically, the three Jay picks are each pinning their hopes on big pharma castoff products. CVTX's ranolazine is a Syntex product (purged when Roche bought Syntex), CBST with LLY's daptomycin and I believe the NBIX sleep drug is an AHP drug, sublicensed to DOV which further licensed it to NBIX.



To: Biomaven who wrote (1348)7/25/2000 2:45:26 PM
From: biowa  Respond to of 52153
 
Peter,

If the in vitro data to date (potently bactericidal against most - probably all - Gram positive bacteria, including those that are resistant to everything else in the armentarium, with very slow resistance development) is borne out in the PII/PIII trials currently underway I suspect Lilly will be really, really, really mad. All IMO.

biowa


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News